
Sign up to save your podcasts
Or


Malaria, a preventable mosquito-borne disease, kills 600,000 people annually in Africa, most of them are children under five. Nigeria accounts for 30% of these deaths globally.
This week, the country started administering the R21 malaria vaccine to children aged 5 to 11 months, beginning in Bayelsa and Kebbi states, which have high infection rates. Developed by Oxford University and manufactured in India, the vaccine has 75% efficacy. With 1 million doses donated by Gavi, the campaign is expected to expand nationwide by 2025.
In today’s episode Alan Kasujja speaks to the BBC’s Health reporter Makuochi Okafor who was in Bayelsa this week and Professor Halidou Tinto, who helped to test the vaccine in Burkina Faso.
Presenter: Alan Kasujja. Guests: Makouchi Okafor, Halidou Tinto
By BBC World Service4.8
170170 ratings
Malaria, a preventable mosquito-borne disease, kills 600,000 people annually in Africa, most of them are children under five. Nigeria accounts for 30% of these deaths globally.
This week, the country started administering the R21 malaria vaccine to children aged 5 to 11 months, beginning in Bayelsa and Kebbi states, which have high infection rates. Developed by Oxford University and manufactured in India, the vaccine has 75% efficacy. With 1 million doses donated by Gavi, the campaign is expected to expand nationwide by 2025.
In today’s episode Alan Kasujja speaks to the BBC’s Health reporter Makuochi Okafor who was in Bayelsa this week and Professor Halidou Tinto, who helped to test the vaccine in Burkina Faso.
Presenter: Alan Kasujja. Guests: Makouchi Okafor, Halidou Tinto

7,695 Listeners

1,042 Listeners

382 Listeners

285 Listeners

5,540 Listeners

1,812 Listeners

1,841 Listeners

1,050 Listeners

2,024 Listeners

363 Listeners

739 Listeners

210 Listeners

250 Listeners

544 Listeners

143 Listeners

3,153 Listeners

761 Listeners

66 Listeners

1,636 Listeners

144 Listeners

279 Listeners

24 Listeners